Intermune, Inc.

Alios Biopharma, Inc.

Aligos Therapeutics, Inc.

Janssen Pharmaceutica Nv

Array Biopharma Inc.

Janssen Biopharma, Inc.

F. Hoffmann-la Roche Ag

Janssen Pharmaceuticals, Inc.

Lawrence M Blatt

Leonid Beigelman

Scott D Seiwert

David Bernard Smith

Julian Alexander Symons

Steven Wade Andrews

April L Kennedy

Yutong Jiang

Timothy S Kercher

Ramachandran Radhakrishnan

Natalia Dyatkina

Vladimir Serebryany

Karl Kossen

Bin Wang

Michael Lyon

Hua Tan

Robert J Kaus

Pierre Martin

Kevin Ronald Condroski

Paul Nichols

Weidong Liu

Jin Hong

Andreas Schumacher

C Todd Eary

Tarek Sammakia

Bradley Barnett

Julia Haas

Brad Owen Buckman

Vivek Kumar Rajwanshi

Peter J Stengel

Min Jiang

Rajendra K Pandey

Steven Mark Wenglowsky

Tara Lynn Kieffer

Cornelis Arie Rijnbrand

Osman N Ozes

Chia-Cheng Kao

Julie Krop

Margaret James Koziel

John Fry

Sushmita Mukherjee Chanda

April Layne Kennedy

John Anthony Josey

Benjamin T Woodard

Peter John Stengel

Machender R Madduru

George Andrew Doherty

Bradley R Barnett

Methods of reducing levels of virus molecules and/or treating viral infections include contacting cells with an oligonucleotide inhibitor that targets a cellular host factor that is a target RNA or target protein involved in viral replication. A pharmaceutical composition can include such an oligonucleotide inhibitor in an amount effective for treating an infection, such as a hepatitis B infection or a respiratory virus infection, such as a coronavirus infection.

Methods of reducing virus molecule levels

Disclosed herein are nucleosides, nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a Filoviridae virus infection with one or more nucleosides and/or nucleotide analogs.

Substituted nucleosides, nucleotides and analogs thereof

Various embodiments provide STOPS&#x2122; polymers that are S-antigen transport inhibiting oligonucleotide polymers, processes for making them and methods of using them to treat diseases and conditions. In some embodiments the STOPS&#x2122; modified oligonucleotides include an at least partially phosphorothioated sequence of alternating A and C units having modifications as described herein. The sequence independent antiviral activity against hepatitis B of embodiments of STOPS&#x2122; modified oligonucleotides, as determined by HBsAg Secretion Assay, is greater than that of a reference compound.

S-antigen transport inhibiting oligonucleotide polymers and methods

Disclosed herein are nucleosides, nucleotides and nucleotide analogs, methods of synthesizing the same and methods of treating diseases and/or conditions such as a Coronaviridae virus, a Togaviridae virus, a Hepeviridae virus and/or a Bunyaviridae virus infection with one or more nucleosides, nucleotides and nucleotide analogs.

Disclosed are methods of modulating a stress activated protein kinase (SAPK) system with an active compound, wherein the active compound exhibits low potency for inhibition of at least one p38 MAPK; and wherein the contacting is conducted at a SAPK-modulating concentration that is at a low percentage inhibitory concentration for inhibition of the at least one p38 MAPK by the compound. Also disclosed are derivatives of pirfenidone. These derivatives can modulate a stress activated protein kinase (SAPK) system.

Method of modulating stress-activated protein kinase system

Described herein is a combination that includes compound (A) of the formula and compound (B) of the formula or a pharmaceutically acceptable salt(s) of the foregoing, for ameliorating and/or treating a hepatitis C viral infection.

Hepatitis C viral infection treatment using a combination of compounds

Disclosed herein are pharmaceutical compositions that can include a thionucleotide analog for use in combination therapy with other agents. Also disclosed herein are methods of treating diseases and/or conditions with a pharmaceutical composition that can include a thionucleotide analog in combination therapy with other agents.

Pharmaceutical combinations comprising a thionucleotide analog

The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

Macrocyclic inhibitors of hepatitis C virus replication

Macrocyclic compounds having the structures described herein are useful for inhibiting replication of the hepatitis C virus (HCV). In preferred embodiments, the compounds are active against both the NS3 protease and the NS3 helicase of HCV.

Compounds and methods for inhibiting hepatitis C viral replication

Growing community of inventors

Healdsburg, CA, United States of America

Lawrence M Blatt